Abbott Laboratories (NYSE:ABT) markets everything from Similac baby formula to cataract surgery equipment and its restructuring itself in order to spark revenue growth.
Abbott is a long-standing member of the S&P 500 dividend aristocrats, a collection of companies with a proud history of dividend increases, so investors are right to wonder if sluggish sales tied to a recall last fall are ready to rebound.
In the following slideshow, I include the most important takeaways from Abbott's second-quarter results and highlight the key reasons Abbott may find the second half of this year is better than the first.
Even Abbott may struggle to outperform these top dividend stocks over the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.